评估治疗计划的修改从外科医生的初步建议到多学科瘤委员会在资源有限的环境中对癌症护理的共识
Sajida Qureshi1, Waqas Ahmad Abbasi1, Hira Abdul Jalil1
1Dow Medical College, Dow University of Health Sciences, Karachi 74200, Pakistan.
Current oncology (Toronto, Ont.)
|June 25, 2025
概括
多学科瘤委员会 (MTBs) 强烈同意外科医生的癌症护理建议. 大型治疗方案完善治疗计划,确保一致的,基于证据的患者管理.
科学领域:
- 在瘤学瘤学.
- 医疗保健管理的管理
- 临床决策 - 临床决策
背景情况:
- 多学科瘤委员会 (MTBs) 对于协作性癌症护理至关重要.
- 关于外科医生推与MTB结果一致性的数据有限,特别是在资源有限的环境中.
研究的目的:
- 评估初始外科医生建议和MTB最终治疗计划之间的一致性.
- 评估治疗意图 (治疗与息) 和MTB决策实施的变化.
主要方法:
- 在MTB中讨论的216名患者的回顾性分析 (2021年1月至2023年12月).
- 利用kappa统计和一致性分析来评估协议.
- 专注于治疗意图的转变和实施率.
主要成果:
- 在外科医生和MTB决定之间观察到强烈的一致性 (科恩的卡帕 = 0.89,p < 0.001).
- 在63.4%的病例中,MTB建议修改或取代了外科医生的计划.
- 在100%的病例中,MTB的决定被执行;治疗意图的转变很少发生.
结论:
- 在协作性癌症护理决策中,MTB发挥着至关重要的作用.
- 多病规则确保一致,个性化和基于证据的治疗计划.
- 高的一致性和实施率凸显了MTB在优化患者护理方面的价值.
更多相关视频
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.4K
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.9K
相关概念视频
Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
